查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1864291

月经症候群治疗市场按治疗方法、最终用户和产品形式划分 - 全球预测 2025-2032 年

Premenstrual Syndrome Treatment Market by Treatment Type, End User, Product Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，月经症候群治疗市场将成长至 25.5 亿美元，复合年增长率为 4.47%。

关键市场统计数据
基准年 2024 17.9亿美元
预计年份：2025年 18.7亿美元
预测年份 2032 25.5亿美元
复合年增长率 (%) 4.47%

全面概述影响经月经症候群治疗策略的不断演变的临床复杂性、患者期望和护理路径。

经月经症候群的症状表现复杂多样，涵盖身体不适、情绪障碍和功能障碍等，需要采取多管齐下的治疗方法。随着临床知识的不断发展，人们逐渐揭示了荷尔蒙週期、神经传导物质调节和心理社会因素之间的病理学生理联繫，患者的期望也随之转变，他们希望获得个别化治疗方法，并尽可能减少对日常生活的干扰。因此，目前的治疗方案更加多元化，结合了行为疗法、营养补充剂和成熟的药物疗法，旨在解决整体症状，而非仅仅针对单一症状。

此外，医疗系统和临床医生正在整合远距监测、分级诊疗通讯协定和明确的诊断标准，以缩短干预时间并满足不断变化的患者偏好。这些趋势推动了对兼顾疗效、耐受性和实际应用性的实证治疗方案的需求。因此，从产品开发商到服务提供者，相关人员都在重新调整其临床价值提案，强调日常功能的可衡量改善、有助于提高遵守用药的治疗形式以及补充（而非取代）标准治疗的干预措施。总而言之，这些发展正在为更完善的服务模式和商业性模式奠定基础，这些模式和模式优先考虑以患者为中心的治疗结果和可扩展的交付机制。

快速而变革性的转变推动了数位化、个人化治疗方法和综合护理模式的发展，从而重塑了月经的治疗。

月经症候群 (PMS) 的治疗格局正在经历变革，这主要得益于技术创新、对个人化医疗的重新关注以及临床和消费者健康模式的融合。数位疗法和远端医疗平台能够提供远距认知行为疗法和结构化的生活方式指导，从而扩大非药物疗法的覆盖范围，并有助于提高长期治疗的依从性。同时，营养保健品科学和製剂技术的进步正在提高膳食补充剂的生物利用度和标准化程度，使其成为综合护理计划中可靠的辅助性治疗。

同时，对神经内分泌调控的更深入理解正引领着药物创新，使临床医生能够更便捷地将现有药物类别与标靶行为介入相结合，从而优化获益风险比。医疗系统也正在尝试整合式护理路径，将症状追踪、疗效评估和升级通讯协定纳入其中，以便更好地根据患者需求调整介入强度。这些转变为研发人员和医疗服务提供者带来了新的策略要务。投资数位化、产生真实世界证据以及建立协作式照护框架，对于在不同的支付方和医疗服务环境中实现治疗差异化、展现实际价值至关重要。

评估美国关税到 2025 年对月经症候群 (PMS) 药物供应链韧性、筹资策略和获取动态的累积影响

美国关税政策在2025年之前的变化正在对月经症候群（PMS）治疗产品的供应链和成本结构产生显着影响，尤其是那些依赖国际采购的活性药物成分、特殊辅料和进口膳食补充剂成分的产品。为此，製造商和经销商正努力透过重新评估筹资策略、优先考虑供应多元化以及加快库存优化来减轻额外进口关税的影响。这些营运调整通常包括在可行的情况下暂时将采购重新分配给国内供应商，并重新谈判供应合约以吸收或转嫁额外的到岸成本。

同时，临床服务模式和终端使用者也在做出调整，以维持治疗的可近性和可负担性。医院和专科诊所正在加强采购通讯协定，并强调治疗等效性评估，以确保在某些产品线价格可能波动的情况下，也能确保治疗的连续性。居家照护模式和远距配药正受到越来越多利害关係人的青睐，他们希望在维持病患用药依从性的同时，最大限度地降低与医疗机构供应链相关的不断上涨的成本。最终，关税环境正在强化灵活生产、透明的成本模式以及监管前瞻性对于开发和提供月经症候群 (PMS) 治疗药物的公司的重要性，促使这些公司将策略重点放在增强自身韧性而非短期价格调整上。

关键的细分洞察表明，治疗类型、最终用户趋势和产品形式偏好相互融合，共同决定了月经症候群 (PMS)治疗方法的采纳和实施。

对治疗细分市场的详细分析突显了治疗方法选择、护理环境和产品形式如何相互作用，从而影响临床应用和患者体验。在考虑治疗类型时，认知行为疗法和结构化生活方式管理等非药物疗法在早期疗育路径中发挥日益重要的作用。同时，膳食补充剂占据独特的市场地位，其配方至关重要。胺基酸衍生物、草药萃取物以及维生素和矿物质补充剂各自都有其自身的证据要求和监管考量，这些都会影响临床医生的接受度和患者的信心。此外，按药物类别分類的药物治疗对于中重度症状仍然至关重要，其中复方口服避孕药、GABA类似物和选择性血清素再回收抑制剂（SSRIs）构成了临床实践中治疗方法的基石。

最终用户环境进一步影响药物的选择和给药方式：居家照护环境倾向于采用能够实现自我给药和远端支持的干预措施；医院优先考虑急性症状控制和多学科协作；而专科诊所通常是製定个体化治疗方案和进行高级治疗方案排序的中心。剂型影响着患者的依从性和製剂策略：胶囊、口服溶液和片剂在剂量灵活性、偏好和稳定性方面各有优势，这些优势决定了产品开发的优先顺序。整合这些细分维度表明，成功的产品必须在特定治疗领域内满足证据阈值，同时还要根据不同环境（居家医疗、医院和专科诊所）的实际情况调整产品剂型和给药模式。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和差异化策略路径正在影响治疗优先事项和进入模式。

区域趋势揭示了美洲、欧洲、中东和非洲以及亚太地区在临床实践规范、法规环境和分销基础设施等方面存在的差异，从而形成了不同的战略重点。在美洲，成熟的药物治疗和非药物治疗相结合的医疗模式是其特点，同时，公共和私人支付方的考虑也会影响药物处方集的纳入和辅助性治疗的报销。这种格局促使人们产生证据，以证明能够带来功能性获益并减少后续药物使用的成本效益高的治疗路径。

在欧洲、中东和非洲，分散的法规结构和多元化的支付方环境构成了复杂的准入壁垒，但也促进了区域性创新，尤其是在远端医疗和社区服务能够扩大覆盖范围的地区。本地化生产能力和监管协调工作对于决定哪些剂型和补充剂能够获得市场认可至关重要。与此同时，亚太地区正经历着数位基础设施的快速发展以及对膳食补充剂和具有文化底蕴的草药疗法的强劲需求。加之远距远端医疗模式的加速普及和消费者健康技术的蓬勃发展，企业必须根据各地区的关键临床和支付方趋势调整其监管策略、证据包和分销模式，才能实现产品的持续推广。

月经症候群 (PMS) 治疗生态系统中的竞争与策略公司洞察：识别关键能力、合作机会、监管差异和差距

在经前症候群（月经）治疗领域，竞争地位更取决于产品系列的深度、可靠的实证医学证据以及跨通路伙伴关係，而非单一产品的突破性进展。拥有成熟荷尔蒙和神经调节药物产品组合的製药公司，透过将临床试验结果与真实世界的依从性研究和临床医生合作相结合，保持着竞争优势。同时，能够证明其原料来源稳定、批次间品质可靠且配方达到临床级别的专业营养保健品生产商和合约开发商，对临床医生和大型经销商的吸引力也日益增强。从远端医疗平台到数位化症状追踪器，技术赋能的医疗服务提供者凭藉其整合能力脱颖而出，将行为介入与临床监测和数据收集相结合。

随着製造商寻求将药物治疗方案与数位治疗方法和实证补充剂相结合，以建立全面的治疗路径，这些组成部分之间的策略联盟也变得越来越普遍。监管核准、品质认证和透明的供应链实务仍然是关键的差异化因素，而那些投资于疗效比较研究和与支付方合作的公司则更有能力影响采购决策。最终，能够提供兼具临床可靠性和可扩展交付能力，以适应不同终端用户环境的产品和服务的企业，以获得竞争优势。

为产业领导者提供切实可行的策略建议，以推动PMS治疗和服务交付的普及、优化获取途径并提供综合价值。

产业领导者应优先采取一系列协作行动，以加速产品应用、确保产品可及性，并在临床和商业管道中创造永续价值。首先，投资于将介入措施与功能性结果联繫起来的高品质证据，将有助于提升与临床医生和支付方的合作关係，并促进其融入治疗路径。其次，开发可与药物和补充剂配送相结合的互通性数位工具和远端医疗项目，能够提高患者的用药依从性，并支持长期疗效评估。此外，还应辅以稳健的生产和供应链策略，以减少对单一供应商的依赖，并增强应对力关税和贸易政策变化的能力。

此外，应积极寻求跨领域伙伴关係，将製药专业知识、营养保健品製剂技术和数位化互动相结合，以提供能够反映患者实际需求的多方面治疗方案。应根据不同地区优化市场进入策略，使监管和报销策略与当地医疗保健系统的发展趋势保持一致。最后，落实以患者为中心的产品设计，例如采用适应性强的剂型、易于吞嚥的口服液以及方便使用的胶囊和片剂，将有助于提高产品在包括居家医疗、医院和专科诊所在内的各种医疗环境中的接受度，从而提升实际应用效果和临床疗效。

透明的多方法调查方法为 PMS 治疗分析提供了基础，包括资料收集的检验、专家检验和清晰的分析框架。

本分析采用多方法研究途径，优先考虑对一级资讯来源和二级资讯来源进行三角检验。一级资讯来源包括对临床医生、药房主任、采购人员和技术提供者的结构化访谈，旨在了解他们对治疗效果、交付挑战和推广应用驱动因素的现场观点。二级资讯来源包括同行评审的临床文献、监管指导文件、产品标籤和公共临床试验註册库，用于支持作用机制、安全性特征和治疗定位。资料综合采用主题分析法辨识重复出现的模式，并采用比较评估法揭示区域差异。

透过迭代检验循环来保持分析的严谨性，在循环中，与领域专家讨论初步发现，以完善假设并识别潜在偏差。透过情境分析评估供应链和政策影响，该分析考虑了与关税相关的物流、采购替代方案和采购应对措施，并专注于营运可行性。调查方法强调资讯来源归属和背景考虑的透明度，使相关人员能够确定研究结果对其策略挑战和区域环境的适用性。

综合分析整合了临床趋势、监管影响和商业性讯号，为经前症候群 (PMS) 护理领域的相关人员确定切实可行的下一步措施。

总体而言，经前症候群（月经）治疗格局的演变呈现出向以患者为中心的综合治疗模式转变的趋势，这种模式结合了行为疗法、营养补充剂和药物治疗。临床和治疗方式的创新正在拓展有效的干​​预措施范围，同时，实证医学、品质和互通性的标准也在不断提高。政策和贸易因素凸显了建立具有韧性的供应链和适应性筹资策略的必要性，而区域间法规和治疗模式的差异则表明，个人化规划比一刀切的方法更为重要。

展望未来，相关人员投资于严谨的疗效评估、构建涵盖胶囊、口服液和片剂等多种剂型的灵活产品系列，并利用数位化平台支持患者依从性的利益相关者，将更有能力满足医疗专业人员和患者的期望。製药、营养保健品和数位医疗领域的合作对于将临床潜力转化为切实可行、可扩展的治疗方案至关重要。最终，最成功的策略将平衡科学可靠性和营运灵活性，从而为经月经患者带来显着的日常功能改善。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 推广个人化基因谱分析以进行月经的标靶治疗
  • 将人工智慧驱动的症状预测工具整合到月经症候群管理应用程式中
  • 利用远端医疗扩大咨商系统，改善经月经症候群治疗的可近性
  • CBD和类大麻素製剂在缓解月经症候群（PMS）相关症状的应用日益广泛
  • 将正念减压疗法引入经前症候群治疗通讯协定
  • 微生物组创新－标靶治疗缓解经月经症状严重程度的差异
  • 增加对植物来源原临床试验的投资，以期缓解经前症候群的生理和情绪症状。
  • 制定职场政策，为应对月经症状提供弹性的休假安排
  • 扩大保险覆盖范围，涵盖全面的月经健康护理，包括月经症候群（PMS）管理疗法。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方式分類的月经症候群治疗市场

  • 非药物治疗
    • 认知行为疗法
    • 生活方式管理
    • 营养补充品
      • 胺基酸衍生物
      • 草药萃取物
      • 维生素和矿物质
  • 药物治疗
    • 按药物类别
      • 口服避孕药
      • GABA类似物
      • 选择性血清素再回收抑制剂

第九章 依最终使用者分類的经月经症候群治疗市场

  • 居家医疗环境
  • 医院
  • 专科诊所

第十章 依产品类型月经症候群治疗市场

  • 胶囊
  • 口服液
  • 药片

第十一章 各地区经月经症候群治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 按组别分類的月经症候群治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国经月经症候群治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bayer AG
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Novartis AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market is projected to grow by USD 2.55 billion at a CAGR of 4.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.79 billion
Estimated Year [2025] USD 1.87 billion
Forecast Year [2032] USD 2.55 billion
CAGR (%) 4.47%

Comprehensive contextual overview of the evolving clinical complexities patient expectations and care pathways shaping premenstrual syndrome treatment strategies

Premenstrual syndrome continues to present a complex constellation of symptoms that span physical discomfort, mood disturbance, and functional impairment, demanding multidisciplinary attention. Recent advances in clinical understanding have clarified pathophysiologic pathways that link hormonal cycling, neurotransmitter modulation, and psychosocial triggers, while patient expectations increasingly favor individualized and minimally disruptive interventions. Consequently, care pathways now reflect a broader palette of options that combine behavioral strategies, nutraceuticals, and established pharmacotherapies to address symptom clusters rather than single complaints.

Moreover, health systems and clinicians are responding to shifting patient preferences by integrating remote monitoring, stepped-care protocols, and clearer diagnostic criteria to reduce time to intervention. These trends are amplifying demand for evidence-backed therapeutic alternatives that balance efficacy, tolerability, and real-world usability. As a result, stakeholders from product developers to service providers are reframing clinical value propositions to emphasize measurable improvements in daily functioning, adherence-friendly formats, and interventions that complement rather than replace standard medical care. Taken together, these developments set the stage for more nuanced service models and commercial approaches that prioritize patient-centric outcomes and scalable delivery mechanisms.

Rapid transformative shifts driving digital enablement personalized therapeutic approaches and integrated care models reshaping premenstrual syndrome treatment

The landscape for premenstrual syndrome treatment is undergoing transformative shifts driven by technological innovation, a renewed focus on personalized care, and the convergence of clinical and consumer health paradigms. Digital therapeutics and telehealth platforms are enabling remote cognitive behavioral therapy and structured lifestyle coaching, which in turn are expanding access to non-pharmacological interventions and supporting long-term adherence. Simultaneously, advances in nutraceutical science and formulation techniques are improving the bioavailability and standardization of supplements, thereby making them more credible adjuncts within comprehensive care plans.

In parallel, pharmacological innovation is being informed by deeper insights into neuroendocrine modulation, with clinicians more readily combining established drug classes with targeted behavioral interventions to optimize benefit-risk profiles. Health systems are also experimenting with integrated care pathways that embed symptom tracking, outcome measurement, and stepped escalation protocols to better match intervention intensity to patient needs. These shifts are creating new strategic imperatives for developers and providers: investments in digital enablement, real-world evidence generation, and collaborative care frameworks are becoming essential to differentiate therapeutic offerings and to demonstrate tangible value across diverse payers and delivery settings.

Assessment of the cumulative impact of United States tariffs through 2025 on supply chain resilience procurement strategies and access dynamics for PMS treatments

Tariff policy changes in the United States through 2025 have exerted a measurable influence on the supply chains and cost structures that underpin premenstrual syndrome treatment delivery, particularly for products that rely on internationally sourced active pharmaceutical ingredients, specialty excipients, and imported nutraceutical components. Manufacturers and distributors have responded by reassessing sourcing strategies, prioritizing supplier diversification, and accelerating inventory optimization to mitigate exposure to incremental import duties. These operational adjustments have, in many cases, led to temporary reallocation of sourcing to domestic suppliers where feasible and to renegotiation of supplier agreements to absorb or pass through incremental landed costs.

At the same time, clinical service models and end users have adapted to preserve access and affordability. Hospitals and specialty clinics have tightened procurement protocols and emphasized therapeutic equivalence assessments to maintain continuity of care despite potential price movement in specific product lines. Home care models and remote dispensing have gained traction as stakeholders seek to preserve adherence while minimizing cost inflation associated with facility-based supply chains. Ultimately, the tariff environment has reinforced the importance of flexible manufacturing, transparent cost modeling, and regulatory foresight for companies engaged in developing or delivering treatments for premenstrual syndrome, prompting a strategic focus on resilience rather than short-term repricing.

Key segmentation insights revealing how treatment type end-user dynamics and product form preferences converge to determine therapeutic adoption and delivery for PMS care

A granular view of treatment segmentation highlights how therapeutic choices, care settings, and product formats intersect to shape clinical adoption and patient experience. When considering treatment type, non-pharmacological approaches such as cognitive behavioral therapy and structured lifestyle management play an increasingly central role in early intervention pathways, while nutritional supplements occupy a distinct niche where formulation matters; supplements based on amino acid derivatives, herbal extracts, and vitamins and minerals each present unique evidence requirements and regulatory considerations that influence clinician acceptance and patient trust. Conversely, pharmacological treatments organized by drug class remain essential for moderate to severe symptom profiles, with combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors forming the backbone of therapeutic regimens used in clinical practice.

End-user contexts further modulate preference and delivery: home care settings favor interventions that enable self-administration and remote support, hospitals prioritize acute symptom control and multidisciplinary coordination, and specialty clinics often serve as centers for tailored regimens and advanced therapeutic sequencing. Product form influences adherence and formulation strategy; capsules, oral liquids, and tablets each present distinct advantages related to dosing flexibility, palatability, and stability, which in turn inform product development priorities. Integrating these segmentation dimensions reveals that successful offerings will address evidence thresholds for specific therapeutic classes while aligning product form and delivery models to the operational realities of home care, hospital, and specialty clinic settings.

Regional dynamics and differentiated strategic trajectories across the Americas Europe Middle East & Africa and Asia-Pacific that shape treatment priorities and access models

Regional dynamics reveal differentiated strategic priorities driven by clinical practice norms, regulatory environments, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care models are characterized by a mature mix of pharmacological and non-pharmacological adoption augmented by private and public payer considerations that influence formulary placement and reimbursement of adjunctive therapies. This context incentivizes evidence generation that demonstrates functional benefits and cost-effective care pathways that reduce downstream utilization.

Across Europe, the Middle East and Africa, fragmented regulatory frameworks and diverse payer landscapes create complex entry barriers but also enable region-specific innovation, particularly where telehealth and community-based delivery can expand reach. Local manufacturing capabilities and regulatory harmonization efforts are pivotal in determining which product forms and supplements gain traction. Meanwhile, the Asia-Pacific region combines rapidly expanding digital infrastructure with strong demand for nutraceuticals and culturally embedded herbal approaches, and this is complemented by accelerated adoption of remote care models and consumer-facing health technologies. Taken together, these regional trajectories suggest that companies must tailor regulatory strategies, evidence packages, and distribution models to the predominant clinical and payer dynamics of each geography to achieve sustainable adoption.

Competitive and strategic company insights identifying capability strengths partnership opportunities regulatory differentiators and gaps within the PMS treatment ecosystem

Competitive positioning within the premenstrual syndrome treatment ecosystem is defined less by single product breakthroughs and more by portfolio depth, evidence robustness, and cross-channel partnerships. Pharmaceutical companies with established portfolios in hormonal and neuro-modulatory classes retain advantages when they pair clinical trial outcomes with real-world adherence programs and clinician engagement. At the same time, specialist nutraceutical manufacturers and contract developers that can demonstrate consistent sourcing, batch-to-batch quality, and clinical-grade formulation are increasingly attractive to both clinicians and large-scale distributors. Technology-enabled providers-ranging from teletherapy platforms to digital symptom trackers-are differentiating through integration capabilities that link behavioral interventions with clinical oversight and data capture.

Strategic collaborations between these constituents are becoming more common, as manufacturers seek to bundle pharmacological options with digital therapeutics or evidence-based supplementation to create comprehensive care pathways. Regulatory approvals, quality certifications, and transparent supply chain practices continue to be key differentiators, and companies that invest in comparative-effectiveness research and payer engagement are better positioned to influence procurement decisions. Ultimately, competitive advantage accrues to organizations that can align clinical credibility with scalable delivery and that can adapt product and service offerings to diverse end-user settings.

Actionable strategic recommendations for industry leaders to enhance adoption optimize access and deliver integrated value across PMS therapeutic and service offerings

Industry leaders should prioritize a set of coordinated actions that accelerate adoption, preserve access, and create durable value across clinical and commercial channels. First, investing in high-quality evidence that links interventions to functional outcomes will strengthen positioning with clinicians and payers and will facilitate integration into care pathways. Second, developing interoperable digital tools and telehealth-enabled programs that can be bundled with pharmacological or supplement offerings will improve adherence and support longitudinal outcome measurement. These capabilities should be complemented by robust manufacturing and supply chain strategies that reduce dependence on single-source imports and that enhance responsiveness to tariff or trade-policy shifts.

In addition, organizations ought to pursue cross-sector partnerships that combine pharmaceutical expertise, nutraceutical formulation, and digital engagement to offer multi-modal therapeutic packages that reflect real-world patient needs. Strategic market entry should be regionally tailored, with regulatory and reimbursement strategies aligned to local health system dynamics. Finally, operationalizing patient-centric product design-through adaptable dosing formats, palatable oral liquids, and user-friendly capsule or tablet options-will increase acceptance across home care, hospital, and specialty clinic settings, thereby improving real-world uptake and clinical impact.

Transparent multi-method research methodology outlining data collection triangulation expert validation and analytical frameworks underpinning the PMS treatment analysis

This analysis was developed using a multi-method research approach that prioritized triangulation and validation across primary and secondary sources. Primary inputs included structured interviews with clinicians, pharmacy leaders, procurement specialists, and technology providers to capture frontline perspectives on therapeutic effectiveness, delivery challenges, and adoption drivers. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, product labeling, and publicly available clinical trial registries to corroborate mechanism-of-action, safety profiles, and therapeutic positioning. Data synthesis relied on thematic analysis to identify recurring patterns and on comparative assessment to surface region-specific distinctions.

Analytical rigor was maintained through iterative validation cycles, wherein preliminary findings were reviewed with domain experts to refine assumptions and to identify potential bias. Supply chain and policy impacts were assessed through scenario analysis that considered tariff-related logistics, sourcing alternatives, and procurement responses, with attention to operational feasibility. The methodology emphasizes transparency in source attribution and contextual caveats so that stakeholders can judge the applicability of findings to their strategic questions and regional contexts.

Concluding synthesis integrating clinical trends regulatory influences and commercial signals to define pragmatic next steps for stakeholders in PMS care

In synthesis, the evolving landscape for premenstrual syndrome treatment is defined by a move toward integrated, patient-centered care that blends behavioral, nutraceutical, and pharmacological approaches. Clinical and delivery innovations are expanding the range of viable interventions while also raising the bar for evidence, quality, and interoperability. Policy and trade factors have highlighted the need for resilient supply chains and adaptive procurement strategies, and regional differences in regulation and care models underscore the necessity of tailored plans rather than one-size-fits-all rollouts.

Looking ahead, stakeholders who invest in rigorous outcome measurement, who build flexible product portfolios spanning capsules, oral liquids, and tablets, and who leverage digital platforms to support adherence will be best positioned to meet clinician and patient expectations. Collaboration across pharmaceutical, nutraceutical, and digital health domains will be essential to convert clinical promise into practical, scalable care. Ultimately, the most successful strategies will be those that balance scientific credibility with operational agility and that deliver demonstrable improvements in daily functioning for individuals affected by premenstrual syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rise of personalized genetic profiling for targeted premenstrual syndrome therapies
  • 5.2. Integration of AI powered symptom prediction tools into premenstrual syndrome management apps
  • 5.3. Expansion of telehealth based consultations for accessible premenstrual syndrome treatments
  • 5.4. Growing adoption of CBD and cannabinoid formulations for alleviating PMS related symptoms
  • 5.5. Integration of mindfulness based stress reduction programs in PMS treatment protocols
  • 5.6. Innovations in microbiome targeted therapies for mitigating premenstrual symptom severity fluctuations
  • 5.7. Increased investment in clinical trials for plant based adaptogens addressing PMS physical and emotional symptoms
  • 5.8. Development of workplace policies offering flexible leave for managing premenstrual syndrome symptoms
  • 5.9. Emergence of insurance coverage expansions for comprehensive menstrual health including PMS management therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premenstrual Syndrome Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological Treatment
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Lifestyle Management
    • 8.1.3. Nutritional Supplements
      • 8.1.3.1. Amino Acid Derivatives
      • 8.1.3.2. Herbal Extracts
      • 8.1.3.3. Vitamins & Minerals
  • 8.2. Pharmacological Treatment
    • 8.2.1. Drug Class
      • 8.2.1.1. Combined Oral Contraceptives
      • 8.2.1.2. Gaba Analogs
      • 8.2.1.3. Selective Serotonin Reuptake Inhibitors

9. Premenstrual Syndrome Treatment Market, by End User

  • 9.1. Home Care Settings
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Premenstrual Syndrome Treatment Market, by Product Form

  • 10.1. Capsule
  • 10.2. Oral Liquid
  • 10.3. Tablet

11. Premenstrual Syndrome Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Premenstrual Syndrome Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Premenstrual Syndrome Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Bayer AG
    • 14.3.2. Pfizer Inc.
    • 14.3.3. Johnson & Johnson Services, Inc.
    • 14.3.4. Eli Lilly and Company
    • 14.3.5. GlaxoSmithKline plc
    • 14.3.6. Teva Pharmaceutical Industries Ltd.
    • 14.3.7. Viatris Inc.
    • 14.3.8. Novartis AG
    • 14.3.9. Sanofi S.A.
    • 14.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GABA ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025-2032 (USD MILLION)
  • TABLE 275. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 282. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 283. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 284. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 285. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-20